Iowa - Pancreatic Cancer Action Network @PanCANIowa

Come see us in Sullivan Park, Waterloo, for Unity in the Community health fair, beginning at 1 pm. We've shared #pancreaticcancer information at this event for at least five years, and this is the best weather!

This Pride Month, explore the resources PanCAN offers to help members of the LGBTQ+ community navigate the healthcare system. 💜 pcan.at/oysbu3

This Men's Health Month, share this post or tag a man you care about. Raising awareness of #pancreaticcancer symptoms and risk factors can help save lives. 💜

Attention researchers! ‼️ Three funding opportunities are now available through the Pancreatic Cancer Research Program at the Department of Defense's (DoD) Congressionally Directed Medical Research Program. Thanks to the advocacy of the PanCAN community, this dedicated #pancreaticcancer research program has not only been reinstated, but was funded at a record breaking $20 million this year — $5 million more than ever before. The first deadlines for two funding mechanisms are approaching in just two weeks! 🔬 Idea Development Award Pre‑Application (Pre‑proposal) due: July 7, 2026 🔬 Translational Research Partnership Award Pre‑Application (Pre‑proposal) due: July 7, 2026 The deadline for pre‑application (letter of intent) is approaching in several months for the following mechanism: 🔬 Focused Pilot Award Pre‑Application (Letter of Intent) due: September 16, 2026 Researchers, apply today at 🔗 ebrap.org/eBRAP/public/P… and spread the word to your colleagues and trainees about these important funding opportunities for pancreatic cancer research. 💜

Sharing story of Iowans inspired by #pancreaticcancer to help others

KCCI News @KCCINews

a month ago

State of Cancer: Iowa families launch Cancer Screen Iowa to improve awareness for screenings | Click on the image to read the full story kcci.com/article/cancer…

1 0 5 2K 0

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26

Daraxonrasib is poised to become the new standard of care for previously treated metastatic pancreatic cancer after detailed results from a Phase III clinical trial were released at the ASCO annual meeting this weekend. 💊 bit.ly/4dZQRT5

Thank you @ASCO for a memorable #ASCO26! 💜

ASCO @ASCO

a month ago

#ASCO26 truly embodied the theme of translating science into global patient outcomes. We are grateful to the ~46,000 attendees, all working tirelessly to conquer cancer together! A heartfelt thanks to all. 💗 We can’t wait to see you next year at #ASCO27!

10 40 125 22K 3

We are entering a pivotal moment for #pancreaticcancer research funding and your advocacy is essential. 📣 The Labor-HHS appropriations bill — which determines funding levels for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) — is the backbone of federal biomedical and cancer research investment. The NCI is also the single largest source of pancreatic cancer research funding in the country. The discoveries, clinical advances and promising therapies we are seeing today are only possible because of sustained federal support over many years. And this week, lawmakers are making critical decisions. Change the story of pancreatic cancer by contacting your members of Congress today at 🔗 pcan.at/yavvkov4. Make sure federally funded research for patients and families is a national priority. 💜

"The results presented at the American Society of Clinical Oncology (@ASCO) Annual Meeting #ASCO26 for daraxonrasib represent the most significant advance we have ever seen in #pancreaticcancer. For a disease that has long been marked by limited treatment options and often devastating outcomes, seeing a therapy double overall survival in previously treated metastatic pancreatic cancer patients is both extraordinary and encouraging. I had the privilege of being in the room when these data were presented and joined colleagues from across the #cancer community in a standing ovation — a rare and powerful moment that reflected the significance of what we were witnessing. It was not simply a celebration of a promising new treatment, but of years of scientific persistence, collaboration and the courage of the patients and families who participated in clinical trials to help move the field forward. We congratulate our valued industry partner, @RevMedicines, as well as the investigators, clinicians and trial participants who made this achievement possible. While there is still much work ahead and no single breakthrough will solve pancreatic cancer alone, these results offer something our community urgently needs: evidence-based hope and a clear reminder that progress is possible." — @JulieFleshman, PanCAN President and CEO Learn more about the additional data on daraxonrasib released at ASCO and how PanCAN Patient Services can help at 🔗 pcan.at/rjul9sza. 💜 📽️: TWC_Network

For the most common type of #pancreaticcancer, pancreatic ductal adenocarcinoma, more than 90% of tumors are thought to have a KRAS mutation. For decades, these mutations were considered “undruggable,” meaning there was no effective way to target them with treatments. But groundbreaking research has changed that with remarkable results — a new RAS inhibitor approximately doubled overall survival compared with chemotherapy in patients with metastatic pancreatic cancer. Join PanCAN to discuss the current moment in KRAS research — and what the newest discoveries may mean for patients now and in the future. During our free virtual event, you'll learn more about: 🧬 What KRAS is and why it's critical for patients diagnosed with pancreatic cancer to know if their tumor has a KRAS mutation 🔬 The latest research related to KRAS and beyond, including clinical trials happening now that stand to change the treatment landscape 🧪 The important role patients play in advocating for biomarker testing, clinical trials and new treatment options for KRAS-driven cancers 💜 How PanCAN Patient Services can help patients get biomarker testing to identify KRAS and other mutations as well as navigate treatment options, including clinical trials Save your virtual seat today at 🔗 pancan.org/facing-pancrea…

#PanCANPurpleStride hasn't met its $17 million goal yet — but you have the power to help get us there. Every dollar you raise or donate brings us one step closer to our fundraising goal and the first milestone of our All Together We Can campaign! It is the most exciting time in #pancreaticcancer research, and we need to seize this moment together. That’s why PanCAN has launched All Together We Can, our $250 million campaign to change the story of this disease for patients and families. Every dollar you raise or donate to help PurpleStride reach goal goes toward our ambitious goal to accelerate advances in research and get every patient access to the care, support and treatments that give them the best chance to survive. 💜 Let’s continue rewriting the story for pancreatic cancer, together at 🔗 purplestride.org! 👟

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit explains why we are in a new era of progress against pancreatic cancer. 🔬 bit.ly/3RPcfmy

Join us in celebrating Asian American and Pacific Islander Heritage Month! 💜 The AAPI community is rich in diverse cultures, languages and experiences. As a result, this community faces diverse needs, challenges and disparities in accessing cancer care. For a disease as complex as #pancreaticcancer, having a provider you trust is essential. Our PanCAN Patient Services team can connect you or a loved one with specialists in your area or who speak your language. Call 📞 (310) 340-6707 or 📧 email [email protected] to connect with a compassionate Case Manager for free, one-on-one support and resources.

Through PanCAN's All Together We Can campaign, we're making our boldest investment yet – $250 million over five years – to accelerate research, expand patient support and strengthen the entire #pancreaticcancer field. 💜 pcan.at/all-together-w…

One week ago, you took steps to end pancreatic cancer at #PanCANPurpleStride! 👟💜 We’d love to see your PurpleStride moments — share your photos and memories with us in the comments below. Together, we can continue supporting #pancreaticcancer patients and families every step of the way. There’s still time to make an impact: donate to a PurpleStride participant, team or event through June 30 at 🔗 purplestride.org.

keyboard_arrow_left Previous keyboard_arrow_right Next

I am delighted by the FDA’s decision to allow initiation of an expanded access treatment protocol for @RevMedicine's daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma, as it represents an important additional pathway for patients with limited options.

PanCAN @PanCAN

3 months ago

Today, the U.S. Food and Drug Administration (FDA) announced that it has issued a “safe to proceed” letter to @RevMedicines, allowing the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib for patients with previously treated metastatic pancreatic

2 12 23 7K 2

Today, the U.S. Food and Drug Administration (FDA) announced that it has issued a “safe to proceed” letter to @RevMedicines, allowing the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). 💊 Expanded access is a potential pathway for patients with serious or life-threatening conditions to gain access to investigational medicines outside of a clinical trial when they are unable to participate in a clinical trial and all other appropriate treatment options have been exhausted. In response to the FDA’s letter, Revolution Medicines said that this “represents a critical step in the process of opening an EAP” and that they are “moving as quickly as possible to ensure safe and equitable access to daraxonrasib for eligible patients in the United States,” according to a statement from the company. Read Revolution Medicines’ Expanded Access Policy, including how to submit a request through a licensed treating physician and how daraxonrasib is extending survival for #pancreaticcancer patients at 🔗 pcan.at/rjul9sza.

PanCAN is leading large-scale, groundbreaking research initiatives that will be the catalyst for transforming the way #pancreaticcancer is detected and treated. No single pancreatic cancer organization has taken on such a comprehensive approach. As an unbiased stakeholder, we're uniquely positioned to bring together the nation’s key thought leaders and experts in pancreatic cancer research to help patients thrive. 🔬💜 This Cancer Research Month, visit 🔗 pancan.org/research to learn more about PanCAN's research commitment.